摘要
目的研究舒肝健骨方对应用芳香化酶抑制剂(aromatase inhibitors,Als)内分泌治疗后出现骨量减少的绝经后乳腺癌患者骨密度(bone mineral density,BMD)和血清骨代谢生化标志物的影响。方法 采用随机数字表法将38例应用Als内分泌治疗的绝经后乳腺癌患者分为治疗组(21例)和对照组(17例),两组均补充钙尔奇D片(含元素钙600 mg和VitD3 125 IU),每日1片。治疗组同时给予舒肝健骨方颗粒剂6 g,每日2次,连续服药6个月。检测治疗前及用药6个月后患者BMD水平,采用酶联免疫法(E LISA)测定骨碱性磷酸酶(BALP)、骨钙素(BGP)、血清抗酒石酸酸性磷酸酶(TRAP)、Ⅱ型胶原C端肽(CTX-Ⅱ)水平,并评价用药的安全性。结果与本组治疗前比较,用药6个月后,治疗组腰椎(L2-4)、股骨颈BMD明显上升(P<0.01),血清BALP、BGP、TRAP下降(P<0.05);对照组腰椎及股骨颈BMD降低(P<0.05),血清BALP、TRAP水平上升(P<0.01)。与对照组比较,治疗6个月后,治疗组腰椎及股骨颈B MD明显升高,血清BGP、BALP水平降低(P<0.01),CTx-Ⅱ、TRAP水平升高(P<0.01)。治疗期间未出现明显不良反应。对照组发生骨折1例(5.8%)。结论舒肝健骨方可减轻Als内分泌治疗的绝经后乳腺癌患者的骨丢失,提高BMD,改善骨代谢异常。
Objective To study the effect of Shugan Jiangu Recipe（SJR） on bone mineral density（BMD） and serum bone metabolic biochemical markers in postmenopausal breast cancer patients with osteopenia.Methods Totally 38 patients of postmenopausal women with breast cancer,who received aromatase inhibitors（Als）,were assigned to the treatment group（21 cases） and the control group（17 cases） by using random digit table.All patients took Caltrate D Tablet（containing Ca 600 mg and Vit D_3 125 IU）,one tablet daily.Patients in the treatment group took SJR,6 g each time,twice daily for 6 successive months.The bone mineral density（BMD） level was detected before treatment and at months 6 after treatment.Levels of bone alkaline phosphatase（BALP）,bone gla protein（BGP）,tartrate-resistant acid phosphatase（TRAP）,and C-terminal telopeptide of type Ⅱ collagen（CTX-Ⅱ） were detected by enzyme linked immunosorbent assay（ELISA）.The drug safety was also assessed.Results Compared with before treatment,BMD of L_（2_4） and femur neck obviously increased in the treatment group at month 6 after treatment（P〈0.01）,serum BALP and TRAP decreased（P〈0.05）.Compared with before treatment,BMD of L_（2-4） and femur neck obviously decreased in the control group at month 6 after treatment（P〈0.05）,serum BALP and TRAP increased（P〈0.01）.Compared with the control group,lumbar and femur neck BMD obviously increased,serum levels of BGP and BALP obviously decreased,and serum levels of CTX-Ⅱ and TRAP obviously increased in the treatment group at month 6 after treatment（P〈0.01）.No serious adverse event occurred during the treatment period.Bone fracture occurred in one case of the control group（5.8%）.Conclusion SJR could attenuate bone loss of postmenopausal women with breast cancer who received Als,increase BMD and improve abnormal bone metabolism.
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2014年第9期1064-1068,共5页
Chinese Journal of Integrated Traditional and Western Medicine
基金
北京市中医药科技项目(No.QN2013-04)
